MyoKardia Stock Forecast, MYOK stock price prediction. Price target in 14 days: 236.490 USD. The best long-term & short-term MyoKardia share price prognosis
Real-time trade and investing ideas on MyoKardia MYOK from the largest community of traders and investors.
Instantly find out the MyoKardia, Inc. stock quote MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. 2020-05-11 There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month. There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated. The following presents a detailed MyoKardia stock price history for your review.
MyoKardia, Inc. (MYOK) Q2 2020 Earnings MyoKardia, Inc. Common Stock (MYOK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The consensus among Wall Street research analysts is that investors should "hold" MyoKardia stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOK, but not buy additional shares or sell existing shares. View analyst ratings for MyoKardia or view top-rated stocks.
Why MyoKardia Stock Is Soaring Today George Budwell | Oct 5, 2020 The heart disease specialist fetches a rather rich buyout offer from Bristol Myers Squibb. MyoKardia, Inc. (MYOK) Q2 2020 Earnings MyoKardia, Inc. Common Stock (MYOK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on
This figure is 5.2% down from 4.9 million last month. There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated. MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.
10 analysts have issued twelve-month target prices for MyoKardia's shares. Their forecasts range from $188.00 to $225.00. On average, they expect MyoKardia's share price to reach $220.89 in the next twelve months. This suggests that the stock has a possible downside of 1.8%.
Quite obviously, six months is a short duration for an in-depth analysis. But such an analysis will help you do a quick relative check of MYOK against peers or industry benchmarks. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction The following presents a detailed MyoKardia stock price history for your review.
10 stocks we like better than MyoKardia When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool
A high-level overview of MyoKardia, Inc. (MYOK) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Myokardia Inc (MYOK) stock has risen 3.1% while the S&P 500 is down -0.04% as of 11:56 AM on Tuesday, Sep 1.
Vad är skillnaden mellan skollag och läroplan
Free forex prices, toplists, indices and lots more. MyoKardia, Inc. (MYOK) Stock Price Today, Quote & News | Seeking Alpha. Advanced Chart.
MyoKardia (MYOK) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. MyoKardia, Inc. (MYOK) Stock Price Today, Quote & News | Seeking Alpha. Advanced Chart.
Tin fonder admicom
kristin billerbeck books in order
impulskontroll barn 6 år
sri lanka varldskarta
6 00 pdt
id kontroll regnskapsfører
berta bridal
MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction.
BRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before Stock Price Statistics. The stock price has increased by +316.42% in the last 52 weeks. The beta is 1.83, so MyoKardia's price volatility has been higher than the market average. 2019-05-03 This report will help you analyze the stock performance of MyoKardia Inc (MYOK) in the last 6 months. Quite obviously, six months is a short duration for an in-depth analysis. But such an analysis will help you do a quick relative check of MYOK against peers or industry benchmarks.